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Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is best known for its selective cytotoxicity against
transformed tumor cells. Most non-transformed primary cells and several cancer cell lines are not only resistant to death
receptor-induced apoptosis, but also subject to inﬂammatory responses in a nuclear factor-jB (NF-jB)-dependent manner.
Although the involvement of TRAIL in a variety of vascular disorders has been proposed, the exact molecular mechanisms are
unclear. Here, we aimed to delineate the role of TRAIL in inﬂammatory vascular response. We also sought possible molecular
mechanisms to identify potential targets for the prevention and treatment of post-angioplastic restenosis and atherosclerosis.
Treatment with TRAIL increased the expression of intercellular adhesion molecule-1 by primary human vascular smooth muscle
cells via protein kinase C (PKC)d and NF-jB activation. Following detailed analysis using various PKCd mutants, we determined
that PKCd activation was mediated by caspase-dependent proteolysis. The protective role of PKCd was further conﬁrmed in
post-traumatic vascular remodeling in vivo. We propose that the TRAIL/TRAIL receptor system has a critical role in the
pathogenesisofinﬂammatoryvasculardisordersbytransducingpro-inﬂammatorysignalsviacaspase-mediatedPKCdcleavage
and subsequent NF-jB activation.
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Abnormal proliferation of vascular smooth muscle cells
(VSMCs) and accumulation of inﬂammatory cells are charac-
teristic features of atherosclerosis and in-stent restenosis.
1
Activated monocytes and macrophages secrete various
pro-inﬂammatory cytokines and growth factors, which stimu-
late the migration and proliferation of VSMCs.
2 Circumstantial
evidence supports the involvement of tumor necrosis factor
(TNF) superfamily members in this process.
3,4 The TNF
superfamily of cytokines activates various signaling pathways
involving cell survival, death, and differentiation, as well as
inﬂammation and immune responses. Recently, TNF-related
apoptosis-inducing ligand (TRAIL) was reported to exert
biological responses other than apoptosis, such as the
induction of pro-inﬂammatory responses by astrocytoma
and the proliferation of VSMCs through activation of the
nuclear factor-kB (NF-kB) pathway,
5–7 although how TRAIL
activates the NF-kB pathway in VSMCs is currently unclear.
TNF-a and tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL), members of the TNF family of cytokines, have
been implicated in the development of atherosclerosis;
4,8,9
whereas genetic ablation of TRAIL has been shown to
attenuate the development of atherosclerosis in apolipo-
protein E-deﬁcient mice.
10
We have previously demonstrated that TRAIL and its
receptors are involved in pro-angiogenic and pro-inﬂamma-
tory signals of human astrocytoma cells.
5,11 Alternative
functions of TRAIL and other TNF superfamily cytokines have
beenimplicatedintumorevasionfromhostimmunesystem.
12
Considering the ubiquitous expression of TRAIL receptors,
the TRAIL-TRAIL receptor system might be involved in a
variety of pathological conditions such as atherosclerosis.
4 In
this study, we demonstrated that TRAIL can be pro-inﬂamma-
tory and pro-atherogenic by showing that TRAIL ligation
induces intercellular adhesion molecule-1 (ICAM-1) expres-
sion and subsequent monocytic adhesion by VSMCs via the
activation of caspases and NF-kB. We also identiﬁed protein
kinase C (PKC)d as a molecular link between caspases and
downstream NF-kB signals.
Results
TRAIL potentiates monocytic adhesion to VSMCs via the
induction of ICAM-1 expression. FACS analysis revealed
that the VSMCs expressed all four TRAIL receptors
(Figure 1a). Consistent with the in vitro data, the VSMCs of
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www.nature.com/cddisthe pulmonary artery expressed TRAIL-R2/DR5, an agonistic
TRAIL receptor, in vivo (Figure 1b). We investigated whether
TRAIL acted as an inﬂammatory mediator in VSMCs. As
determined by FACS analysis, we observed a marked
increase in the level of ICAM-1 expression by VSMCs in
response to TRAIL (Figure 1c). This effect was comparable
to that of TNF-a, a well-known pro-inﬂammatory cytokine.
TRAIL-mediated ICAM-1 expression was markedly inhibited
by pretreatment with a soluble DR5 decoy receptor
(Supplementary Figure 1). Treatment with TRAIL or TNF-a
signiﬁcantly increased monocytic adhesion to VSMCs
(Figure 1d), consistent with the increase in ICAM-1
expression. Blockade of CD18 completely inhibited
monocytic adhesion to VSMCs in response to TRAIL
stimulation, indicating that ICAM-1 and (lymphocyte
function-associated antigen-1 or CD11a/CD18) or Mac-1
(CD11b/CD18) interactions have key roles in TRAIL-
mediated monocytic adhesion.
We next evaluated the ability of TRAIL to induce apoptosis
in VSMCs. Treatment with TRAIL scarcely induced apoptotic
cell death of VSMC. Although TRAIL did not induce signiﬁcant
cell death, the active fragment of caspase-3 was detected
within 1h of treatment with TRAIL by immunoblot analysis.
Treatment with MG-132, a proteasome inhibitor that accumu-
lates active caspase-3,
13 markedly enhanced the TRAIL-
mediated cleavage of caspase-3 (Figure 1e) and subsequent
cell death (Supplementary Figure 2). The cleavage of active
caspase-3 was completely abrogated by pretreatment with
zVAD-fmk. Collectively, these results indicate that the death
domain-containing TRAIL receptors expressed by VSMCs do
not induce apoptotic cell death, but rather pro-inﬂammatory
responses, even though TRAIL ligation triggers caspase-3
activation.
TRAIL induces the activation of NF-jB and subsequent
expression of ICAM-1 in a caspase-dependent manner.
. Because TRAIL treatment induced caspase-3 cleavage in
the absence of overt cytotoxicity, we next examined the
involvement of caspases in TRAIL-induced ICAM-1
expression. Enhanced expression of ICAM-1 upon TRAIL
stimulation was signiﬁcantly blocked by pretreatment with a
broad-spectrum caspase inhibitor zVAD-fmk, as well as
speciﬁc inhibitors for caspase-8 and -3 (i.e. zIETD-fmk and
zDEVD-fmk, respectively; Figure 2a). In contrast,
pretreatment with zVAD-fmk did not inhibit TNF-a-induced
expression of ICAM-1 in VSMCs.
To determine whether caspase cascades are involved in
NF-kB activation, we tested the combined effects of two
differentinhibitors(i.e. zVAD-fmkþNF-kBinhibitor)onICAM-
1 expression. As shown in Figure 2b, suppression of TRAIL-
mediated ICAM-1 expression by zVAD-fmk was not further
affected by addition of NF-kB inhibitors such as SN-50 or
lactacystin. Cells pretreated with zVAD-fmk showed a
signiﬁcant decrease in phosphorylation of IkB kinase (IKK)
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Figure 1 TRAIL-induced monocytic adhesion to VSMCs via the expression of ICAM-1. (a) VSMCs were examined by ﬂow cytometry for the expression of TRAIL
receptors. (b) A normal human pulmonary artery was stained for TRAIL-R2, and nuclei were counterstained with hematoxylin. Scale bar¼100mm. (c) Cells were incubated
withTRAIL(500mg/l)orTNF-a(10mg/l)for24handICAM-1expressionwasevaluatedbyﬂowcytometry.MFI,meanﬂuorescenceintensity.(d)VSMCswereincubatedinthe
absence or presence of TRAIL and TNF-a for 24h, incubated with anti-CD18 antibody for an additional 1h, and then stained with Hoechst 33258. Activated U937 cells were
allowed to adhere to the VSMCs. A P-value is indicated when the difference was statistically signiﬁcant (Student’s t-test). (e) VSMCs were incubated in the absence or
presence of MG-132 or zVAD-fmk (zVAD; 20mmol/l) for 1h and then treated with TRAIL for various time periods. Cell lysates were examined by immunoblot analysis for
caspase-3. b-Actin protein was used as a loading control
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Cell Death and Diseaseand inhibitor of kB( I kB), which are important steps in the
activation of NF-kB (Figure 2c). In contrast, TNF-a-induced
phosphorylation of these molecules was not affected by
pretreatment with zVAD-fmk. Treatment of VSMCs with
TRAIL or TNF-a induced the degradation of IkBa and the
subsequent nuclear translocation of the NF-kB p65 subunit
within 60min following treatment (Figure 2d). The extent of
p65 translocation into the nucleus in response to TRAIL
decreasedsigniﬁcantlyinthepresenceofzVAD-fmkorNF-kB
inhibitorssuchasSN-50andlactacystin.InthecaseofTNF-a,
p65 translocation was signiﬁcantly blocked only by NF-kB
inhibitors, but not caspase inhibitors.
PKCd acts downstream of caspases in the TRAIL-
mediated NF-jB pathway. Various studies have
demonstrated a critical role of PKC isoforms in the NF-kB
pathway at the level of IKK activation and IkB
degradation.
14,15. Human VSMCs expressed considerably
high levels of PKCa and PKCd; whereas PKCb isoform
was not detected by immunoblot analysis (Supplementary
Figure 3a). Cells transfected with PKCd siRNA displayed a
signiﬁcant reduction in TRAIL-induced phosphorylation
of IKK and the subsequent phosphorylation of IkB;
whereas transfection with control siRNA or siRNAs speciﬁc
for PKCa or PKCb had little effect on TRAIL-induced
phosphorylation of IKK and IkB (Figure 3a and
Supplementary Figure 3b). Because PKCd is known to be
proteolytically activated by caspases, we next determined
whether TRAIL ligation could activate PKCd through
cleavage by caspases. Immunoblot analysis demonstrated
that TRAIL ligation induced a time-dependent proteolytic
cleavage of PKCd to produce a short carboxy-terminus
fragment (41kDa; Supplementary Figure 4). The caspase-
dependent cleavage of PKCd was further conﬁrmed by
introducing a PKCd
D329A construct, which has a mutation in
the caspase cleavage site (Figure 3b).
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Figure 2 TRAIL induced the activation of NF-kB and subsequent expression of ICAM-1 in a caspase-dependent manner. (a) Cells were incubated in the absence or
presence of the caspase inhibitors zVAD-fmk, zIETD-fmk (zIETD), and zDEVD-fmk (zDEVD) (20mmol/l) for 1h, and then treated with TRAIL or TNF-a for an additional 24h.
ICAM-1 protein was measured by ﬂow cytometry. (*) a signiﬁcant difference compared with the sample treated with TRAIL alone. *Po0.0001, **P¼0.002, ***P¼0.034;
Tukey’s post-hoc test was applied to signiﬁcant group effects in analysis of variance (ANOVA), F6, 19¼51.234, Po0.0001 for the ﬂow cytometric analysis. (b) Cells were
incubated in the absence or presence of the caspase inhibitor zVAD-fmk (zVAD; 20mmol/l) for 1h, pretreated with SN-50 (50mg/l) or lactacystin (10mmol/l) for 1h, and then
treated with TRAIL for 24h. ICAM-1 protein was measured by ﬂow cytometry. (*) a signiﬁcant difference compared with the sample treated with TRAIL alone. *P¼0.001,
**Po0.0001;Tukey’spost-hoctestwas appliedtosigniﬁcantgroupeffectsinANOVA(F8,9¼40.456,Po0.0001)fortheﬂowcytometricanalysis.(c)VSMCswereincubated
intheabsenceorpresenceofzVAD-fmk(zVAD;20mmol/l)for1handtreatedwithtrailorTNF-aforvarioustimeperiods(0–60min);thencelllysateswereanalyzedforp-IKK,
IKK, p-IkBa, and IkBa by immunoblotting. (d) VSMCs were incubated in the absence or presence of zVAD-fmk, SN-50 (50mg/l), and lactacystin (lacta; 10mmol/l), then
treated with TRAIL or TNF-a for 60 or 30min, respectively. Cells were stained with an anti-p65 antibody via an immunocytochemical method
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Cell Death and DiseaseTo determine whether caspase-dependent cleavage of
PKCd is required for TRAIL-induced NF-kB activation, we
performed a NF-kB reporter assay following the introduction
of wild-type PKCd and PKCd
D394A constructs. As expected,
TRAIL but not TNF-a failed to increase the NF-kB reporter
activity after the introduction of the PKCd
D394A construct
(Figure 3c). To directly conﬁrm the role of active PKCd
fragment released by proteolytic cleavage, we generated a
truncation mutant representing the caspase-cleaved catalytic
fragment of PKCd, so-called PKCd-CF. The introduction of
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Cell Death and DiseasePKCd-CF signiﬁcantly increased the NF-kB activation as
compared with the construct control or PKCd wild-type;
whereas TRAIL ligation further increased the NF-kB activity
(Figure 3d). These results clearly demonstrate that the
caspase-dependent generation of catalytic fragment of PKCd
is required for TRAIL-induced NF-kB activation.
Although PKCs are known to directly phosphorylate the IKK
responsible for NF-kB activation, it is also proposed that
NAD(P)H oxidase (Nox) regulation of PKCs leads to NF-kB
activation through reactive oxygen species (ROS) genera-
tion.
16 Because we have observed the proteolytic cleavage of
PKCdandgenerationofintracellularROSuponTRAILligation
(Supplementary Figure 5), we investigated the involvement of
Nox in the NF-kB pathway. We examined the knockdown
effects of Nox4, a major vascular Nox subunit, on NF-kB
activation and subsequent ICAM-1 expression. Cells trans-
fected with Nox4 siRNA exhibited a signiﬁcant reduction in
TRAIL-induced activity of the NF-kB reporter gene, indicating
that the Nox4 isoform mediates NF-kB activation induced by
TRAIL (Figure 3d). In addition, Nox4 knockdown signiﬁcantly
suppressed TRAIL-induced ICAM-1 expression (Figure 3e).
The NF-kB activation and subsequent ICAM-1 expression
induced by TNF-a also suppressed by Nox4 siRNA transfec-
tion are consistent with a previous report stating that
Nox facilitates the redox-dependent induction of NF-kBb y
TNF-a.
17 Knockdown of Nox1, another vascular Nox subnit,
suppressed only TNF-a-induced ICAM-1 expression but not
that induced by TRAIL ligation, suggesting the differential
involvement of Nox isoform (Supplementary Figure 6).
The observations described here suggest that PKCd has a
criticalroleinNF-kB-mediated ICAM-1expressioninduced by
the pro-inﬂammatory cytokine, TRAIL. Therefore, to demon-
strate the involvement of PKCd in post-traumatic vascular
remodeling process, in which an acute pro-inﬂammatory
response is critical, neointimal growth was analyzed following
the in vivo transfection of PKCd siRNA in an arterial injury
model. Quantitative histomorphometric analysis clearly
showed a signiﬁcant reduction in the neointimal/medial area
ratio in PKCd siRNA-transfected vessels as compared with
control vessels (Figure 3f).
Discussion
Current ﬁndings suggest a novel role of PKCd in the
TRAIL-mediated signal transduction pathway that leads to
caspase-dependent NF-kB activation by VSMCs (Figure 4).
We conﬁrmed that TRAIL ligation induced expression of the
NF-kB-responsive pro-inﬂammatory gene, ICAM-1, which
has an important role in the regulation of inﬂammatory
responses. Even though TRAIL ligation can also induce
ICAM-1 expression by human astrocytoma cells in a similar
manner, the major role of TRAIL system is to induce an
apoptotic cell death, which can be regulated by various
intracellular signaling such as the Nox-ROS pathways.
18,19
On the contrary, the limited potential of TRAIL to induce
apoptotic cell death suggests the involvement of the TRAIL
system in the pathogenesis of inﬂammatory vascular dis-
orders including atherosclerosis and post-angioplastic rest-
enosis.
7,9 This study prompts further evaluation of TRAIL and
PKCd as novel therapeutic targets for development of
medications to treat chronic inﬂammatory vascular disorders.
Recent reports suggest non-apoptotic roles of caspases by
cleavageofunidentiﬁedintermediatessoastotransducenon-
apoptotic signals.
20,21 This hypothesis is supported by the
observation that caspase-8 is involved in the cleavage of IkB
between Asp
31 and Ser,
32 leading to the activation of
NF-kB.
22 Another study demonstrated that IKK complex
recruitment and activation, as well as the nuclear transloca-
tion of NF-kB, require the enzymatic activity of full-length
caspase-8, and that caspase-8 deﬁciency abolishes the
activation of NF-kB after stimulation through Toll-like recep-
tors in immune cells.
23,24 Recent evidence also suggests that
PKCd acts as a pro-survival factor in the process of
apoptosis,
25–27 although numerous reports have revealed a
role for PKCd as a mediator of the cell death program. SMCs
of the expanding neointima from PKCb-null mice were growth
restricted whereas PKCd-null mice exhibited signiﬁcantly
higher numbers of SMCs, supporting the notion that PKCd
generally suppresses normal cell proliferation.
28 In contrast,
our results showed that transfection of PKCd siRNA signi-
ﬁcantly reduced the neointimal thickness, suggesting that the
PKCd-mediated inﬂammatory response is crucial to post-
traumatic vascular remodeling in response to acute injury.
Collectively, these observations indicate that PKCd and
caspases might have distinct functions in the regulation of
cell proliferation and apoptosis in a context-dependent
manner.
Despite the fact that caspase activation is a key feature of
TRAIL signaling in VSMCs, we did not observe TRAIL-
induced apoptotic cell death in VSMCs. The resistance of
Figure3 Caspase-dependentcleavageofPKCdisresponsibleforTRAIL-inducedNF-kBactivation.(a)VSMCstransfectedwithscrambledcontrolsiRNAorPKC-speciﬁc
siRNA were treated with TRAIL for various time periods (0–90min) and the cell lysates were analyzed for p-IKK, IKK, p-IkBa,I kBa, PKCd, and b-actin by immunoblotting. A
representative of two independent experiments is shown. (b) VSMCs were transfected with PKCd constructs (PKCd wild-type (WT); PKCd
D394A, DA; PKCd-CF, CF) for 16h
andthentreatedwithTRAILfor4h.CelllysatesweresubjectedtoimmunoblotanalysisforFlag,PKCd,andb-actin.(c)VSMCsweretransfectedwithPKCdconstructs(PKCd
WT; PKCd-CF, CF) and a NF-kB luciferase reporter plasmid for 16h and treated with TRAIL for 6h. Cells were lysed and a luciferase assay was performed. A P-value is
indicated (Student’s t-test). Samples signiﬁcantly different from the control sample were indicated with symbols (*Po0.01; **Po0.001). Data indicate the mean of four
samples from a representative among three independent experiments. (d) VSMCs were transfected with PKCd constructs (PKCd WT; PKCd
D394A, DA) and a NF-kB
luciferase reporter plasmid for 16h and treated with TRAIL or TNF-a for 6h. Cells were lysed and a luciferase assay was performed. A P-value is indicated (Student’s t-test).
Samples signiﬁcantly different from the control sample were indicated with symbols (*Po0.01; **Po0.001). Data indicate the mean of four samples from a representative
amongfourindependentexperiments.(e)VSMCsweretransfectedwithNox4siRNAandaNF-kBluciferasereporterplasmidfor24handtreatedwithTRAILorTNF-afor6h.
Cells were lysed and a luciferase assay was performed. A P-value is indicated when the difference was statistically signiﬁcant (Student’s t-test). The Nox4 mRNA level was
determined by qPCR.(f)Cells transfectedwith scrambledcontrol siRNAor Nox4-speciﬁcsiRNA weretreatedwith TRAIL or TNF-a for 24h. ICAM-1proteinwas measured by
ﬂow cytometry. A P-value is indicated when the difference was statistically signiﬁcant (Student’s t-test). (g) Transfection mixtures of control siRNA or PKCd siRNA were
injected along the carotid artery after balloon injury of the artery. Ten days after the injury, the arterial tissue was isolated and stained with hematoxylin and eosin. The intimal
and medial areas were determined and the ratio of intima to media was calculated
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Cell Death and DiseaseVSMCs to TRAIL-mediated apoptosis can be explained by
several mechanisms. First, sensitivity to TRAIL-mediated
apoptosis can be determined at the receptor level.
29 TRAIL,
either as a type II transmembrane protein or as a soluble
protein, interacts with four different transmembrane recep-
tors, namely TRAIL-R1 and TRAIL-R2 (which transmit
apoptotic signals) and TRAIL-R3 and TRAIL-R4 (which lack
a functional death domain and therefore function as decoy
receptors to protect cells from apoptosis).
30 According to our
results, TRAIL-R2 is expressed most highly by VSMCs, and
the levels of TRAIL-R3 and -R4 are negligible in TRAIL-
resistant VSMCs. Therefore, we can exclude the increased
expression of decoy receptors as a possible mechanism for
TRAIL resistance of VSMCs. Second, high levels of cellular
FLICE inhibitory protein (c-FLIP) or X-linked inhibitor of
apoptosis protein (XIAP), endogenous inhibitors of caspase-
8 and -3, may be responsible for resistance to TRAIL-
mediated cell death.
31,32 Some studies have shown an
increased expression of FLIP by Fas-resistant SMCs.
33
However, increased levels of c-FLIP or XIAP block not only
TRAIL-mediated cell death, but also the activation of caspase
itself. We can exclude the possibility that the TRAIL-resistant
mechanism is mediated by c-FLIP or XIAP expression
because TRAIL ligation induces the activation of caspase-3
in VSMCs.
Our results demonstrated that proteasome inhibition
sensitized VSMCs to TRAIL-induced cell death. Treatment
with TRAIL scarcely induced VSMC cell death, whereas this
effect was markedly enhanced by the presence of the protein
synthesis inhibitor cycloheximide or the proteasome inhibitor
MG-132 (Supplementary Figure 4A). Cells pretreated with the
proteasome inhibitor lactacystin showed a similar pattern of
caspase cleavage as cells pretreated with MG-132 (Supple-
mentary Figure 4B). In contrast, cells pretreated with SN-50,
which inhibits nuclear translocation of NF-kB, showed no
increase in the active form of caspase-3 in the presence of
TRAIL.TheseﬁndingssuggestthatNF-kBinhibitionbySN-50
may not affect caspase-3 activation, but rather proteasome
inhibition by MG-132 or lactacystin may increase the active
form of caspase-3 bystabilizing the molecule.
13 These results
revealed that accumulated active caspase-3 by proteasomal
inhibition can trigger apoptotic cell death in TRAIL signaling,
whereas the death domain-containing TRAIL receptors
expressed by VSMCs do not cause apoptotic cell death, even
though TRAIL ligation induces caspase-3 activation.
Recent evidence suggests that TRAIL promotes the
proliferation of VSMCs via activation of the NF-kB pathway,
7
although how TRAIL activates the NF-kB pathway in VSMCs
is currently unclear. The results described here suggest the
involvement of caspase-dependent PKCd activation in the
TRAIL-mediated NF-kB pathway. Although a mechanism for
direct NF-kB activation induced by the upstream PKC exists,
we tested the additional involvement of a Nox isoform in the
NF-kB pathway based on the rationale that Nox-dependent
ROS generation is also important for NF-kB activation. The
concept that ROS regulate gene expression appears to be
generally accepted, particularly in regard to NF-kB activation
by pro-inﬂammatory cytokines.
34 To speculate that the
expression of the pro-inﬂammatory gene ICAM-1 following
TRAIL stimulation is regulated by intracellular ROS is
TRAIL
DR5
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PKCδ CF
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￿ Inflammation
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Figure 4 Proposed model of TRAIL signaling pathway responsible for ICAM-1 expression
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Cell Death and Diseasetempting. This hypothesis is supported by the ﬁnding that
TRAIL produces intracellular ROS in a time-dependent
manner (Supplementary Figure 5) and that TRAIL-induced
NF-kB activation and subsequent ICAM-1 expression are
suppressed by Nox4 siRNA transfection (Figures 3d and e). A
mechanism through which an increase in ROS level following
TRAIL stimulation could affect the activation of NF-kB
remains to be clariﬁed. Given that many kinases in the
NF-kB pathway are redoxsensitive, ROS may activate NF-kB
by regulating upstream signaling, which leads to the
phosphorylation of IkB. Alternatively, the NF-kB subunit itself,
as well as the upstream kinase of IkB in the NF-kB pathway,
maybedirectlymodiﬁedbyROS.
35Inaddition,weobserveda
differential involvement of Nox isoforms in ICAM-1 expres-
sion. Nox4 knockdown signiﬁcantly suppressed TRAIL-
induced ICAM-1 expression, whereas Nox1 siRNA had an
inhibitory effect only on TNF-a-induced ICAM-1 expression
(Figure 3e and Supplementary Figure 6). These results
suggest that Nox1 and Nox4 differentially regulate the TRAIL
and TNF-a-signaling pathways; Nox1 is only involved in the
TNF-a-mediated signaling pathway, whereas Nox4 affects
both TRAIL and TNF-a signaling.
ROS, such as superoxide anions and hydrogen peroxide,
are generated inside cells in response to physiological
stimulation by growth factors and cytokines.
36 Evidence
suggests that ROS are responsible for cytokine-induced
NF-kB activation, although relatively little is known regarding
the molecular mechanisms by which cytokine stimulation
might increase ROS levels and subsequent NF-kB activa-
tion.
37 The multicomponent enzyme Nox is regarded as a
major source of ROS responsible for various cell signaling. Its
activation is regulated by the phosphorylation of cytosolic
components, which is mainly mediated by several PKC
isoforms.
38 Among these, PKCd is ubiquitously expressed as
a Ser/Thr kinase of the PKC superfamily and has been
implicated in the control of wide physiological responses,
including VSMC homeostasis.
39
Nox has emerged as a major source of ROS in the
cardiovascular system, although the precise molecular
mechanisms responsible for receptor-mediated generation
of ROS are not fully understood. Most vascular cells express
multiple Nox proteins, including gp91phox (also known as
Nox2), Nox1, Nox4 and Nox5.
36 Of these, Nox4, which is
strongly expressed in all cells of the vascular wall, appears to
be important for ligand-induced production of hydrogen
peroxide.
40 Nonetheless, little is known regarding the speciﬁc
mechanism of Nox4 activation. Previous studies have
demonstrated that PKCd serves as a key substrate for
caspase-3 during apoptotic cell death.
41 Caspase-3 cleaves
thekinasetoyielda41-kDacatalyticallyactivefragmentanda
37-kDa regulatory fragment, which continuously activate the
kinase.
41 We hypothesized a potential mechanism in which
caspase regulation of ROS generation occurs through
caspase-dependent activation of PKCd. As expected, casp-
ase was found to be essential for PKCd cleavage, which
induces an increase in ROS and subsequent ICAM-1
expression, thereby indicating that PKCd acts as a link
between caspase and Nox activation for NF-kB activation.
Atthepresenttime,Nox4 hasnoknownregulatory subunit,so
how the cleaved PKCd affects the activation of Nox4 remains
to be discovered. Recently, a mechanism for p47phox
phosphorylation in the activation of Nox isoforms was
reported.
42 This raises the possibility that p47phox is involved
in PKC-mediated activation of Nox upon TRAIL stimulation.
Materials and Methods
Cell culture and reagents. Human aortic smooth muscle cells were
purchased from LONZA (Walkersville, MD, USA) and cultured in the medium
provided by the company. The experiments were performed with cells that were
cultured for six to seven passages. Human recombinant TRAIL and TNF-a were
obtained from R&D Systems (Minneapolis, MN, USA). TRAIL-R2/DR5 response
was examined using soluble DR5:Fc chimera (Alexis corporation, San Diego, CA,
USA). Cycloheximide and MG-132 were purchased from Calbiochem (La Jolla, CA,
USA).NF-kBinhibitorsincludingSN-50andlactacystinwerefromBiomolResearch
Laboratories(PlymouthMeeting,PA,USA), andCalbiochem,respectively.Rottlerin
and the caspase inhibitors, which included zVAD-fmk, zIETD-fmk, and zDEVD-fmk,
were purchased from Calbiochem.
Flow cytometric analysis. For analysis of TRAIL receptors expression,
VSMCs were trypsinized, suspended in PBS that contained 3% fetal bovine serum,
and incubated with anti-human TRAIL-R1, TRAIL-R2, TRAIL-R3, or TRAIL-R4
antibody for 1h (Alexis Biochemicals, Lausanne, Switzerland). VSMCs were
washed and stained with phycoerythrin (PE)-conjugated anti-mouse IgG1 (BD
Biosciences, San Jose, CA, USA) for an additional 1h, washed again, and then
analyzed by FACStar (BD Biosciences). A PE-conjugated, isotype-matched (IgG1)
antibody (BD Biosciences) was used as a negative control. Within 30min of
staining, 10000 cells were analyzed by FACStar .
For analysis of ICAM-1 expression, VSMCswere trypsinized,suspendedin PBS
that contained 3% fetal bovine serum, and incubated with PE-conjugated anti-
ICAM-1 antibody (BD Biosciences). VSMCs were washed and stained with
phycoerythrin (PE)-conjugated anti-mouse IgG1 (BD Biosciences) for an additional
1h, washed again, and then analyzed by FACStar. A PE-conjugated, isotype-
matched (IgG1) antibody (BD Biosciences) was used as a negative control. Cell
death was determined by staining with Annexin V-ﬂuorescein isothiocyanate and
propodium iodide (BD Biosciences), as described previously.
5 Within 30min of
staining, 10000 cells were analyzed by FACStar .
Immunohistochemistry. Normal human pulmonary arteries were
embedded in parafﬁn and cut into 5-mm-thick sections. The specimens were
washed with PBS and incubated for 1h with mouse anti-TRAIL-receptors
antibodies, which were pre-diluted in PBS with horse serum. Biotin-labeled
secondaryantibodieswere applied for 30min,followedby avidin–biotin–peroxidase
complex (ABC kit; Vector Laboratories, Burlingame, CA, USA). Normal mouse IgG1
(Clontech, Palo Alto, CA, USA) was used as the control. Cell nuclei were
counterstained with hematoxylin. The study using human pulmonary artery
conforms with the principles outlined in the Declaration of Helsinki and was
approved by the Institutional Review Board of Mokdong Medical Center (Ewha
Womans University).
Adhesion assay. Human monocytic U937 cells were activated with
lipopolysaccharide (100mg/l) for 24h, and stained with 1mmol/l TMRE
(Invitrogen, Carlsbad, CA, USA) for 10min. The U937 cells were then allowed to
adhere to VSMCs. After 30min, the cells were washed to remove non-adherent
U937 cells. Adherent U937 cells were analyzed under an inverted ﬂuorescence
microscope. In the blocking experiments, U937 cells were pre-incubated with anti-
CD18 antibody (Calbiochem) for 1h before cell adhesion. Mouse IgG1 was used as
an isotype control antibody (BD Biosciences).
Western blot analysis. Total cell extracts (20mg of total protein) were
prepared and electrophoresed in 12% SDS gels, as described previously.
5 The
proteins were then transferred to nitrocellulose membranes and probed with
antibodies directed against human caspase-3, DYKDDDDK (Flag) tag, phospho-
IKK (p-IKK), IKK, phospho-IkBa (p-IkBa), and IkBa (Cell Signaling Technology,
Beverly, MA, USA). The anti-PKCd and anti-b-actin antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Enhanced
chemiluminescence was used to detect the bound antibodies (AbFrontier, Seoul,
Korea).
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using Lipofectamine(Invitrogen), according to the manufacturer’s protocol. The siRNA
oligonucleotides that encode Nox1, Nox4, and PKCd were obtained from Bioneer
(Daejeon, Korea), and the sequences were described in Supplementary Table 1
(Bioneer). At 48h post-transfection, total RNA was extracted from transfected cells using
the Trizol reagent (Gibco BRL, Grand Island, NY, USA). The cDNA derived from 1mgo f
total RNA was subjected to RT-PCR with the following Nox4-speciﬁc primers
(Supplementary Table 2). Conventional PCR reactions were performed using an initial
denaturation step at 951C (5min) followed by 23 cycles of 941C( 2 0s ) ,5 6 1C (30s), and
721C (30s). Quantitative PCR was performed with a real-time PCR system (Applied
Biosystems, CA, USA). Each reaction was done in triplicate using a reaction solution
containing SYBR Green buffer and the primers (0.3mmol/l, Supplementary Table 3). The
mRNA level was normalized by that of GAPDH.
Human wild-type PKCd was cloned into pCMV-3Tag-3A, and a mutation in the
caspase cleavage site (pCMV-3Tag-PKCdD-A329) was generated from pCMV-
3Tag-PKCd by PCR site-directed mutagenesis using a Quick Change site-directed
mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s
protocol.Thecatalyticfragmentofwild-typePKCdwasgeneratedbyPCRusingfull-
length pCMV-3Tag-PKCd as a template, starting at the caspase cleavage site
(amino acid residue 378).
43 For NF-kB reporter assay, cells were transfected with
the reporter plasmids NF-kB luciferase by using Lipofectamine and then treated
withTRAILorTNF-a.After6htreatmentcellswerelysedaccordingtotheluciferase
assay system with lysis buffer protocol (Promega, Madison, WI, USA).
Luminescence from the lysates was measured by Wallac multilabel counter
(PerkinElmer Wallac, Gaithersburg, MD, USA).
Nuclear location of p65NF-jB by immunocytochemistry. Nuclear
translocation of p65 was observed by the immunocytochemical method. Treated
cells were ﬁxed with 4% paraformaldehyde, and permeabilized with 0.2% of Triton
X-100 (Sigma, St. Louis, MO, USA). After being washed in PBS, slides were
blocked with 2% bovine albumin serum for 1h and then incubated with rabbit
polyclonal anti-human p65 (Santa Cruz) at 1:100 dilutions. After overnight
incubation at 41C, the slides were washed and incubated with goat anti-rabbit IgG-
ﬂuorescein isothiocyanate (Santa Cruz) at 1:500 dilutions for 1h.
Rat balloon-injured model. A balloon injury was created with an inﬁltrated
2F Fogarty balloon catheter (ACS RX Comet, Advanced Cardiovascular System,
Inc., Temecula, CA, USA) in the normal left rat carotid artery as described
previously.
44 Ten-week-old male Sprague-Dawley rats were anaesthetized, the left
external carotid artery was exposed, and its branches were electro-coagulated. A
catheter was pushed 1cm in through the transverse arteriotomy of the external
carotid artery, and the endothelial denudation was achieved by three passes along
the common carotid artery. Transfection mixtures (PKCd siRNA or Control siRNA,
200nmol/l) were prepared using siPORT NeoFX reagent following the
manufacturer’s instructions (Ambion, Austin, TX, USA). Balloon-injured region
was washed with 200ml opti-MEM by punched balloon catheter. Each transfection
mixtures in punched balloon catheter were injected along the common carotid
artery. After 15min incubation, blood ﬂow in occluded left common carotid artery
was reperfused. Rottlerin (50mmol/l) in situ transfection experiment was
accomplished in similar procedures. One week or 10 days after the injury and
siRNA transfection, the common carotid arteries were excised after transcardiac
perfusion ﬁxation with heparinized saline containing 3.7% formaldehyde, and
parafﬁn embedded. Five serial tissue sections (100-mm interval and 4-mm
thickness) were obtained from the middle area of common carotid arteries. Each
slide was stained with haematoxylin and eosin. All experiments were conducted in
compliance with the Guide for the Care and Use of Laboratory Animals of Ewha
Women’s University, Seoul, Korea. The investigation conforms to the Guide for the
Care and Use of Laboratory Animals published by the US National Institutes of
Health (NIH Publication no. 85-23, revised 1996).
Statistical analysis. Data are presented as the mean±S.D. Levels of
signiﬁcance for comparisons between two independent samples were determined
using the Student’s t-test. Groups were compared by analysis of variance with
Tukey’s honestly signiﬁcant difference post-hoc test applied to signiﬁcant main
effects (SPSS 12.0K for Windows; SPSS Inc., Chicago, IL, USA).
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